Dr. Sanjay Ahuja, MD, MSc, MBA
Claim this profileUniversity Hospitals Health System Cleveland
Studies Hemophilia A
Studies Hemophilia B
5 reported clinical trials
6 drugs studied
Area of expertise
1Hemophilia A
FVIII Level positive
FVIII Gene Mutation positive
2Hemophilia B
Affiliated Hospitals
Clinical Trials Sanjay Ahuja, MD, MSc, MBA is currently running
SEVENFACT®
for Hemophilia
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Recruiting3 awards Phase 46 criteria
rVWF +/− ADVATE
for Von Willebrand Disease
The main aim of the study is to check effectiveness, side effects, and tolerability of recombinant von Willebrand Factor (rVWF), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with rVWF for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be followed up at clinics or over telephone calls.
Recruiting2 awards Phase 3
More about Sanjay Ahuja, MD, MSc, MBA
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sanjay Ahuja, MD, MSc, MBA has experience with
- PEGylated Recombinant Factor VIII
- ITI
- Antihemophilic Factor (Recombinant)
- Von Willebrand Factor (Recombinant)
- Clotting Factor Replacement Product
- Coagulation Factor VIIa [recombinant]-jncw
Breakdown of trials Sanjay Ahuja, MD, MSc, MBA has run
Hemophilia A
Hemophilia B
Von Willebrand Disease
Hemophilia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sanjay Ahuja, MD, MSc, MBA specialize in?
Sanjay Ahuja, MD, MSc, MBA focuses on Hemophilia A and Hemophilia B. In particular, much of their work with Hemophilia A has involved FVIII Level positive patients, or patients who are FVIII Gene Mutation positive.
Is Sanjay Ahuja, MD, MSc, MBA currently recruiting for clinical trials?
Yes, Sanjay Ahuja, MD, MSc, MBA is currently recruiting for 2 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Sanjay Ahuja, MD, MSc, MBA has studied deeply?
Yes, Sanjay Ahuja, MD, MSc, MBA has studied treatments such as PEGylated Recombinant Factor VIII, ITI, Antihemophilic Factor (Recombinant).
What is the best way to schedule an appointment with Sanjay Ahuja, MD, MSc, MBA?
Apply for one of the trials that Sanjay Ahuja, MD, MSc, MBA is conducting.
What is the office address of Sanjay Ahuja, MD, MSc, MBA?
The office of Sanjay Ahuja, MD, MSc, MBA is located at: University Hospitals Health System Cleveland, Cleveland, Ohio 44106 United States. This is the address for their practice at the University Hospitals Health System Cleveland.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.